A trial of targeted drugs for chronic myeloid leukaemia when treatment has stopped working (TASTER)

Cancer type:

Blood cancers

Chronic leukaemia

Chronic myeloid leukaemia (CML)

Leukaemia

Status:

Results

Phase:

Phase 2

This trial was for people with chronic myeloid leukaemia. It looked at adding a targeted drug to the targeted drug people were already taking.

It was open to people with chronic myeloid leukaemia (CML):

whose treatment had stopped working
that had the Philadelphia chromosome and is in the chronic phase stage or accelerated phase stage

Cancer Research UK supported this trial.

More about this trial

When this trial was done, doctors could treat chronic myeloid leukaemia (CML) with one of the following:

These targeted drugs Open a glossary item are cancer growth blockers called tyrosine kinase inhibitors (TKIs). Tyrosine kinase is a protein that acts as a messenger to stimulate cancer cells to grow. TKIs block these messages.

Sometimes these drugs stop working. So researchers were looking for other drugs to help people in this situation. In this trial, they are looked at other TKI's

The aims of this trial were to find out:

how well adding a newer drug works
what the side effects are
how it affects quality of life

Summary of results

There aren't any results available for this trial. This was because it closed earlier than planned as it was difficult to recruit patients to take part.